



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : P Lalitanzova, Asst Drugs Inspector (F and D)
CMO Office,
Lawngtlai District- 796891, Mizoram
- Serial No. and date of Inspector's memorandum : 020/IPA-LTI/II-25, 15-APR-2025
- Number of Sample : NIL
- Date of receipt : 06-MAY-2025
- Names of drugs purporting to be contained in the sample : Calcium & Vitamin D3 Tablets I.P. (Caldicare)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0543	GUW/LS/2025-26/559	TA240006	Jan-2024 Dec-2025	NA	Orchid Medilife Pvt. Ltd., (WHO GMP & GLP CERTIFIED COMPANY) Khasra No. 646/513, Vill. Kaundi, P.O. Thana, Tehsil Baddi, Distt. Solan (H.P.) 173205

- Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

- Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 21-May-2025 To 07-Jul-2025

COMPOSITION : Each film coated tablet contains:
Calcium carbonate I.P. 1250 mg eq. to Elemental Calcium 500 mg

Protocol Applied : I.P.2022

Sr No.	Test Name	Result	Limits
1	Description	Blue colored, elongated, bi-convex, scored on one surface, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Calcium & Vitamin D3.	NA
3	Average weight	1.6335 g	NA
4	Uniformity of weight	Complies.	+5 % of Average weight
5	Dissolution (Calcium)	Complies.	NLT 70 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
-------	-----------------	-------	-------	------------	--------	--------------------

1	Calcium Carbonate Eq. to Elemental Calcium	509.5 mg/Tablet	500 mg/Tablet	101.9	90 % to 110 %	I.P.2022
2	Vitamin D3	228.57 IU / Tablet	250 IU / Tablet	91.428	NLT 90 %	I.P.2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P.2022 in respect of test performed.

Date: 07-AUG-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

